UBS Group’s Loncar China BioPharma ETF CHNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-252
| Closed | -$4.73K | – | 9601 |
|
|
2022
Q4 | $4.73K | Sell |
252
-859
| -77% | -$16.1K | ﹤0.01% | 8091 |
|
|
2022
Q3 | $16K | Sell |
1,111
-512
| -32% | -$7.37K | ﹤0.01% | 6643 |
|
|
2022
Q2 | $32K | Buy |
1,623
+806
| +99% | +$15.9K | ﹤0.01% | 5316 |
|
|
2022
Q1 | $17K | Sell |
817
-278
| -25% | -$5.79K | ﹤0.01% | 6646 |
|
|
2021
Q4 | $29K | Buy |
1,095
+141
| +15% | +$3.73K | ﹤0.01% | 6328 |
|
|
2021
Q3 | $36K | Buy |
+954
| New | +$36K | ﹤0.01% | 5488 |
|
|
2021
Q2 | – | Sell |
-1,681
| Closed | -$62K | – | 8741 |
|
|
2021
Q1 | $62K | Buy |
1,681
+1,291
| +331% | +$47.6K | ﹤0.01% | 5348 |
|
|
2020
Q4 | $13K | Sell |
390
-494
| -56% | -$16.5K | ﹤0.01% | 6279 |
|
|
2020
Q3 | $27K | Buy |
884
+541
| +158% | +$16.5K | ﹤0.01% | 5226 |
|
|
2020
Q2 | $11K | Sell |
343
-805
| -70% | -$25.8K | ﹤0.01% | 6112 |
|
|
2020
Q1 | $26K | Buy |
1,148
+416
| +57% | +$9.42K | ﹤0.01% | 5438 |
|
|
2019
Q4 | $18K | Buy |
+732
| New | +$18K | ﹤0.01% | 5886 |
|
|
2018
Q4 | – | Sell |
-436
| Closed | -$10K | – | 7287 |
|
|
2018
Q3 | $10K | Buy |
+436
| New | +$10K | ﹤0.01% | 6262 |
|